New Delhi, June 25 -- Indian pharmaceutical and biotech sectors have started witnessing tangible benefits from the global shift away from China, as early signs of the China+1 strategy materialising emerge, according to a recent Goldman Sachs report.

Some pharmaceutical and biotech companies report that they have started witnessing the conversion of earlier enquiries and Requests for Quotations (RFQs) into pilot projects and small contracts.

The 'China Plus One' strategy is a business technique in which corporations diversify their manufacturing and supply chains by expanding into countries other than China while still keeping a presence in China.

The report was prepared based on the outcome of the '2nd annual India CRO/CDMO trip' event...